Citations

Clear

4207 citation(s) found for "Chen, Yu".

IC‐03‐06: Six month MRI gray matter declines in Alzheimer's dementia evaluated by voxel‐based morphometry with multivariate network analysis: Preliminary findings from the ADNI study
Alexander, Gene E. , Hanson, Krista D., Reiman, Eric M. , Kornak, John , Schuff, Norbert, Weiner, Michael W. , Chen, Kewei , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2008.05.011 Get It

P1‐311: Use of the support vector machine and sensitivity of an Alzheimer's disease‐related region‐of‐interest gray matter classifier in identifying amnestic mild cognitive impairment subjects who convert to Alzheimer's disease: Preliminary findings from t
Zhang, Hang , Bae, Min-Hyeok, Reiman, Eric M. , Alexander, Gene E. , Wu, Tong , Bae, Min Hyeok, Thompson, Paul M. , Jack, Clifford R. , Chen, Kewei

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_9 | Pages: No page available

10.1016/j.jalz.2008.05.902 Get It

P1‐259: Regional hypometabolism in cognitively normal Hispanic carriers of the apolipoprotein E–ϵ4 allele
Reiman, Eric M. , Alexander, Gene E. , Bandy, Daniel, Smilovici, Oded, Lee, Wendy , Recshke, Cole, Caselli, Richard J. , Langbaum, Jessica B. S. , Chen, Kewei , Recshke, Cole

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_9 | Pages: No page available

10.1016/j.jalz.2008.05.849 Get It

P1‐216: Six month MRI gray matter declines in Alzheimer's dementia evaluated by voxel‐based morphometry with multivariate network analysis: Preliminary findings from the Alzheimer's Disease Neuroimaging Initiative
Alexander, Gene E. , Hanson, Krista D., Reiman, Eric M. , Kornak, John , Schuff, Norbert, Weiner, Michael W. , Chen, Kewei , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_8 | Pages: No page available

10.1016/j.jalz.2008.05.805 Get It

Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma
Reece, Donna , Rodriguez, Giovanni Piza, Chen, Christine , Trudel, Suzanne , Kukreti, Vishal , Pantoja, Mariela, Xu, Wei , Stewart, A. Keith, Mıkhael, Joseph

Mayo Clinic

Journal of Clinical Oncology | July 21, 2008 | Volume: 26 | Issue: 29 | Pages: 4777-4783

10.1200/jco.2007.14.2372 | PMID 18645194 Get It

Purpose The combination of oral weekly cyclophosphamide and alternate day prednisone is a convenient regimen for relapsed/refractory multiple myeloma (MM), and we sought to improve its efficacy by adding bortezomib, a proteasome inhibitor with proven antimyeloma activity. Patients and Methods We conducted a phase I-II trial evaluating six dose levels to define the maximum tolerated dose (MTD) of this combination in relapsed/refractory MM. An additional 10 patients were evaluated at the highest dose level reached. Results Thirty-seven patients were treated on this study. The MTD was not defined. Both of the highest dose levels of bortezomib tested (1.3 mg/m 2 on days 1, 4, 8, and 11 and 1.5 mg/m 2 on days 1, 8, and 15, each on a 28-day cycle) could be safely given with cyclophosphamide 300 mg/m 2 per week and prednisone. At these dose levels, the overall response rate was 95% (complete responses [CR] plus partial response plus minimal response), with CR observed in more than 50% of patients. The weekly bortezomib regimen resulted in fewer instances of grade 3 thrombocytopenia and grade 1 to 2 peripheral neuropathy; the 1-year progression-free and overall survival probabilities with this dose level were 83% (95% CI, 73% to 96%) and 100%, respectively. Conclusion Weekly bortezomib 1.5 mg/m 2 plus oral cyclophosphamide and prednisone produces an unprecedented response rate and encouraging 1-year survival in relapsed/refractory patients with MM. Further evaluation of this promising regimen is warranted both in relapsed and newly diagnosed disease.
Eps15 Mediates Vesicle Trafficking from thetrans-Golgi Network via an Interaction with the Clathrin Adaptor AP-1
Chi, Susan , Cao, Hong , McNiven, Mark A. , Chen, Jing

Mayo Clinic

Molecular Biology of the Cell | June 5, 2008 | Volume: 19 | Issue: 8 | Pages: 3564-3575

10.1091/mbc.e07-10-0997 | PMID 18524853 Get It

Eps15 (EGFR pathway substrate clone 15) is well known for its role in clathrin-coated vesicle formation at the plasma membrane through interactions with other clathrin adaptor proteins such as AP-2. Interestingly, we observed that in addition to its plasma membrane localization, Eps15 is also present at the trans-Golgi network (TGN). Therefore, we predicted that Eps15 might associate with clathrin adaptor proteins at the TGN and thereby mediate the formation of Golgi-derived vesicles. Indeed, we have found that Eps15 and the TGN clathrin adaptor AP-1 coimmunoprecipitate from rat liver Golgi fractions. Furthermore, we have identified a 14-amino acid motif near the AP-2–binding domain of Eps15 that is required for binding to AP-1, but not AP-2. Disruption of the Eps15–AP-1 interaction via siRNA knockdown of AP-1 or expression of mutant Eps15 protein, which lacks a 14-amino acid motif representing the AP-1 binding site of Eps15, significantly reduced the exit of secretory proteins from the TGN. Together, these findings indicate that Eps15 plays an important role in clathrin-coated vesicle formation not only at the plasma membrane but also at the TGN during the secretory process.
Angiogenic Function of Prostacyclin Biosynthesis in Human Endothelial Progenitor Cells
He, Tongrong , Lü, Tong , Lam, Chen-Fuh, Lee, Hon-Chi, Katušić, Zvonimir S. , d’Uscio, Livius V. , Lu, Tong

Mayo Clinic

Circulation Research | May 30, 2008 | Volume: 103 | Issue: 1 | Pages: 80-88

10.1161/circresaha.108.176057 | PMID 18511850 Get It

The role of prostaglandin production in the control of regenerative function of endothelial progenitor cells (EPCs) has not been studied. We hypothesized that activation of cyclooxygenase (COX) enzymatic activity and the subsequent production of prostacyclin (PGI 2 ) is an important mechanism responsible for the regenerative function of EPCs. In the present study, we detected high levels of COX-1 protein expression and PGI 2 biosynthesis in human EPCs outgrown from blood mononuclear cells. Expression of COX-2 protein was almost undetectable under basal conditions but significantly elevated after treatment with tumor necrosis factor-α. Condition medium derived from EPCs hyperpolarized human coronary artery smooth muscle cells, similar to the effect of the PGI 2 analog iloprost. The proliferation and in vitro tube formation by EPCs were inhibited by the COX inhibitor indomethacin or by genetic inactivation of COX-1 or PGI 2 synthase with small interfering (si)RNA. Impaired tube formation and cell proliferation induced by inactivation of COX-1 were rescued by the treatment with iloprost or the selective peroxisome proliferator–activated receptor (PPAR)δ agonist GW501516 but not by the selective PGI 2 receptor agonist cicaprost. Downregulation of PPARδ by siRNA also reduced angiogenic capacity of EPCs. Iloprost failed to reverse PPARδ siRNA-induced impairment of angiogenesis. Furthermore, transfection of PGI 2 synthase siRNA, COX-1 siRNA, or PPARδ siRNA into EPCs decreased the capillary formation in vivo after transplantation of human EPCs into the nude mice. These results suggest that activation of COX-1/PGI 2 /PPARδ pathway is an important mechanism underlying proangiogenic function of EPCs.
The immunobiology of cholangiocytes
O’Hara, Steven P. , Chen, Xian‐Ming , LaRusso, Nicholas F.

Mayo Clinic

Immunology & Cell Biology | May 27, 2008 | Volume: 86 | Issue: 6 | Pages: 497-505

10.1038/icb.2008.37 | PMID 18504452 Get It

Cholangiocytes, the epithelial cells lining bile ducts, provide the first line of defense against lumenal microbes in the biliary system. Recent advances in biliary immunity indicate that cholangiocytes express a variety of pathogen‐recognition receptors and can activate a set of intracellular signaling cascades to initiate a profound antimicrobial defense, including release of proinflammatory cytokines and chemokines, production of antimicrobial peptides and maintenance of biliary epithelial integrity. Cholangiocytes also interact with other cell types in the liver (for example, lymphocytes and Kupffer cells) through expression and release of adhesion molecules and immune mediators. Subsequently, through an intricate feedback mechanism involving both epithelial and other liver cells, a set of intracellular signaling pathways are activated to regulate the functional state of cholangiocyte responses during microbial infection. Thus, cholangiocytes are actively involved in mucosal immunity of the biliary system and represent a fine‐tuned, integral component of liver immunity.
Distinct versus overlapping functions of MDC1 and 53BP1 in DNA damage response and tumorigenesis
Minter‐Dykhouse, Katherine, Ward, Irene M., Huen, Michael S.Y. , Chen, Junjie , Lou, Zhenkun

Mayo Clinic

The Journal of Cell Biology | May 27, 2008 | Volume: 181 | Issue: 5 | Pages: 727-735

10.1083/jcb.200801083 | PMID 18504301 Get It

The importance of the DNA damage response (DDR) pathway in development, genomic stability, and tumor suppression is well recognized. Although 53BP1 and MDC1 have been recently identified as critical upstream mediators in the cellular response to DNA double-strand breaks, their relative hierarchy in the ataxia telangiectasia mutated (ATM) signaling cascade remains controversial. To investigate the divergent and potentially overlapping functions of MDC1 and 53BP1 in the ATM response pathway, we generated mice deficient for both genes. Unexpectedly, the loss of both MDC1 and 53BP1 neither significantly increases the severity of defects in DDR nor increases tumor incidence compared with the loss of MDC1 alone. We additionally show that MDC1 regulates 53BP1 foci formation and phosphorylation in response to DNA damage. These results suggest that MDC1 functions as an upstream regulator of 53BP1 in the DDR pathway and in tumor suppression.
A Series of Potent and Selective, Triazolylphenyl-Based Histone Deacetylases Inhibitors with Activity against Pancreatic Cancer Cells and Plasmodium falciparum
Lopez-Sanchez, Miriam, Savoy, Doris N., Billadeau, Daniel D. , Dow, Geoffrey S., Kozikowski, Alan P. , Chen, Yufeng

Mayo Clinic

Journal of Medicinal Chemistry | May 22, 2008 | Volume: 51 | Issue: 12 | Pages: 3437-3448

10.1021/jm701606b | PMID 18494463 Get It